Reports Q3 revenue $169M, consensus $165.71M. “Amicus (FOLD) achieved yet another impressive quarter, delivering revenue growth of 17 percent and reaching the milestone of GAAP profitability. We served more patients than ever before, driven by new Galafold starts and growing adoption for Pombiliti + Opfolda,” said Bradley Campbell, President and Chief Executive Officer, Amicus Therapeutics Inc. “Alongside this commercial momentum, enrollment in the Phase 3 study of DMX-200 remains on track for completion by year-end. Through our continued execution, Amicus is well positioned to achieve our 2025 strategic objectives and deliver sustainable double-digit growth in the years ahead.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- FOLD Upcoming Earnings Report: What to Expect?
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Needham upgrades Amicus to Buy on reduced regulatory risk
- Amicus Stock Upgraded to Buy: DMX-200’s Potential and Galafold’s Growth Drive Investment Opportunity
- Amicus upgraded to Buy from Hold at Needham